221 related articles for article (PubMed ID: 20832916)
1. Structure activity relationship studies of imidazo[1,2-a]pyrazine derivatives against cancer cell lines.
Myadaraboina S; Alla M; Saddanapu V; Bommena VR; Addlagatta A
Eur J Med Chem; 2010 Nov; 45(11):5208-16. PubMed ID: 20832916
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
Garamvölgyi R; Dobos J; Sipos A; Boros S; Illyés E; Baska F; Kékesi L; Szabadkai I; Szántai-Kis C; Kéri G; Őrfi L
Eur J Med Chem; 2016 Jan; 108():623-643. PubMed ID: 26724730
[TBL] [Abstract][Full Text] [Related]
3. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
[TBL] [Abstract][Full Text] [Related]
4. New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
Deleuze-Masquefa C; Moarbess G; Khier S; David N; Gayraud-Paniagua S; Bressolle F; Pinguet F; Bonnet PA
Eur J Med Chem; 2009 Sep; 44(9):3406-11. PubMed ID: 19278757
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro cytotoxic evaluation of some thiazolylbenzimidazole derivatives.
Luo Y; Xiao F; Qian S; Lu W; Yang B
Eur J Med Chem; 2011 Jan; 46(1):417-22. PubMed ID: 21115212
[TBL] [Abstract][Full Text] [Related]
6. Effective synthesis of benzimidazoles-imidazo[1,2-a]pyrazine conjugates: A comparative study of mono-and bis-benzimidazoles for antitumor activity.
Singh I; Luxami V; Paul K
Eur J Med Chem; 2019 Oct; 180():546-561. PubMed ID: 31344614
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of imidazol-2-one derivatives as potential antitumor agents.
Xue N; Yang X; Wu R; Chen J; He Q; Yang B; Lu X; Hu Y
Bioorg Med Chem; 2008 Mar; 16(5):2550-7. PubMed ID: 18226907
[TBL] [Abstract][Full Text] [Related]
8. Novel 5,7-disubstituted 6-amino-5H-pyrrolo[3,2-b]pyrazine-2,3-dicarbonitriles, the promising protein kinase inhibitors with antiproliferative activity.
Dubinina GG; Platonov MO; Golovach SM; Borysko PO; Tolmachov AO; Volovenko YM
Eur J Med Chem; 2006 Jun; 41(6):727-37. PubMed ID: 16675067
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and primary cytotoxicity evaluation of new imidazo[2,1-b]thiazole derivatives.
Gürsoy E; Güzeldemirci NU
Eur J Med Chem; 2007 Mar; 42(3):320-6. PubMed ID: 17145120
[TBL] [Abstract][Full Text] [Related]
10. SAR studies of brasilicardin A for immunosuppressive and cytotoxic activities.
Komatsu K; Tsuda M; Tanaka Y; Mikami Y; Kobayashi J
Bioorg Med Chem; 2005 Mar; 13(5):1507-13. PubMed ID: 15698766
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 2,8-disubstituted imidazo[1,5-a]pyrimidines with potent antitumor activity.
Matsumoto H; Ikeda K; Nagata N; Takayanagi H; Mizuno Y; Tanaka M; Sasaki T
J Med Chem; 1999 May; 42(9):1661-6. PubMed ID: 10229634
[TBL] [Abstract][Full Text] [Related]
12. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.
Bello AM; Konforte D; Poduch E; Furlonger C; Wei L; Liu Y; Lewis M; Pai EF; Paige CJ; Kotra LP
J Med Chem; 2009 Mar; 52(6):1648-58. PubMed ID: 19260677
[TBL] [Abstract][Full Text] [Related]
14. New imidazo[2,1-b]thiazole derivatives: synthesis, in vitro anticancer evaluation, and in silico studies.
Park JH; El-Gamal MI; Lee YS; Oh CH
Eur J Med Chem; 2011 Dec; 46(12):5769-77. PubMed ID: 22033063
[TBL] [Abstract][Full Text] [Related]
15. Spiro[(dihydropyrazin-2,5-dione)-6,3'-(2',3'-dihydrothieno[2,3-b]naphtho-4',9'-dione)]-based cytotoxic agents: structure-activity relationship studies on the substituent at N4-position of the diketopiperazine domain.
Gomez-Monterrey I; Campiglia P; Carotenuto A; Stiuso P; Bertamino A; Sala M; Aquino C; Grieco P; Morello S; Pinto A; Ianelli P; Novellino E
J Med Chem; 2008 May; 51(10):2924-32. PubMed ID: 18429610
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial and cytotoxic activity of agelasine and agelasimine analogs.
Vik A; Hedner E; Charnock C; Tangen LW; Samuelsen Ø; Larsson R; Bohlin L; Gundersen LL
Bioorg Med Chem; 2007 Jun; 15(12):4016-37. PubMed ID: 17442577
[TBL] [Abstract][Full Text] [Related]
17. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
[TBL] [Abstract][Full Text] [Related]
18. [SCA 40 and derivatives: new bronchodilators in an imidazo(1,2-a)pyrazine series].
Bonnet PA; Vitse O; Bénezech V; Subra G; Fabréguettes JR; Zanik L; Laurent F; Michel A; Bompart J; Chapat JP
Ann Pharm Fr; 1998; 56(4):155-9. PubMed ID: 9770008
[TBL] [Abstract][Full Text] [Related]
19. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
